Literature DB >> 31478918

Mortality and Associated Risk Factors in Community-Dwelling Persons With Early Dementia.

Blake Barrett1, Susan K Schultz, Stephen L Luther, Yvonne Friedman, Linda Cowan, Tatjana Bulat.   

Abstract

OBJECTIVE: Examine mortality and associations with baseline characteristics among Veterans with early dementia.
METHODS: Participants included dyads of community-based Veterans with early dementia and their caregivers (N=143) enrolled in a previous longitudinal study. Department of Veterans Health Affairs' electronic records were used to retrospectively collect Veteran mortality outcomes, over a 6-year period. Measures included baseline: demographics, dementia-related factors, other comorbid conditions, functioning, and medication use. Associations with baseline characteristics and mortality were examined with bivariate analyses and a series of Cox proportional hazard models.
RESULTS: Over 6 years of study follow-up, 53.1% of participants died. The mean time to death was 3.09 years, with a range of 54 days to 5.91 years. Female sex, better cognition, and higher scores on the Tinetti Gait and Balance scale were protective factors in the final multivariable model, adjusting for other characteristics.
CONCLUSIONS: While newly diagnosed with early dementia, over half of our sample died in the 6-year follow-up period, with the average death occurring only 3 years after initial diagnosis. The finding of lower mortality associated with better performance on gait/balance testing indicates an important opportunity for focused interventions and early detection of gait and balance changes early during cognitive decline.

Entities:  

Year:  2020        PMID: 31478918     DOI: 10.1097/WAD.0000000000000343

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  1 in total

1.  No effect of thyroid hormones on 5-year mortality in patients with subjective cognitive decline, mild cognitive disorder, and Alzheimer's disease.

Authors:  Blaž Đapić; Eva Schernhammer; Helmuth Haslacher; Elisabeth Stögmann; Johann Lehrner
Journal:  J Neuroendocrinol       Date:  2022-02-25       Impact factor: 3.870

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.